VistaGen Therapeutics, Inc.
VTGN · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | -$0 | $1 |
| % Growth | -54.3% | 568.7% | -120.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $1 | -$0 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $39 | $20 | $44 | $35 |
| G&A Expenses | $17 | $14 | $15 | $10 |
| SG&A Expenses | $17 | $14 | $15 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $3 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $56 | $34 | $59 | $49 |
| Operating Income | -$56 | -$33 | -$59 | -$48 |
| % Margin | -11,517.1% | -3,103.5% | 26,109.3% | -4,308.7% |
| Other Income/Exp. Net | $5 | $4 | $0 | $0 |
| Pre-Tax Income | -$51 | -$29 | -$59 | -$48 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$51 | -$29 | -$59 | -$48 |
| % Margin | -10,579.8% | -2,759.6% | 26,100.4% | -4,307.2% |
| EPS | -1.67 | -1.52 | -8.51 | -7.38 |
| % Growth | -9.9% | 82.1% | -15.3% | – |
| EPS Diluted | -1.67 | -1.52 | -8.51 | -7.38 |
| Weighted Avg Shares Out | 31 | 19 | 7 | 7 |
| Weighted Avg Shares Out Dil | 31 | 19 | 7 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $3 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$55 | -$32 | -$59 | -$47 |
| % Margin | -11,386.4% | -3,050.1% | 25,874.9% | -4,242.8% |